CD8A and glioblastoma: During that trial patients with recurring GBM were treated with a single dose of CAN-3110 and, interestingly, existing HSV-1 seropositivity prior to treatment was correlated to higher CD4 and CD8 T cell infiltration intratumorally and a higher clinical benefit when compared to seronegative patients prior to treatment [44].